Velcade

ApprovedSmall molecule

Takeda

Velcade is one of 490 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Approved.

Indications

Total Trials

Active Trials

489

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaActive, not recruiting

LymphomaActive, not recruiting

LeukemiaActive, not recruiting

AdenocarcinomaActive, not recruiting

Kidney TransplantActive, not recruiting

AmyloidosisActive, not recruiting

T-Cell Prolymphocytic LeukemiaActive, not recruiting

Myelodysplastic SyndromeActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Nasopharyngeal CarcinomaPhase 2

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

LeukemiaPhase 1

Active, not recruiting

AdenocarcinomaPhase 2

Active, not recruiting

Kidney TransplantApproved

Active, not recruiting

AmyloidosisPhase 1/Phase 2

Active, not recruiting

T-Cell Prolymphocytic LeukemiaPhase 2

Active, not recruiting

Myelodysplastic SyndromePhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Breast CancerPhase 1/Phase 2

Active, not recruiting

Showing 10 of 17 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Velcade

Takeda

Approved

1 2

Tecentriq

Roche

Preclinical

36 3

DATROWAY

Daiichi Sankyo

Preclinical

4 4

Lexiscan

Astellas

Preclinical

1 5

Adenocard

Astellas

Preclinical

1 6

Zolymbus

AbbVie

Preclinical

1 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 8

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 9

Acupan

YYonsei University

Preclinical

1 10

Paracetamol

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Trial

NCT00871013

Q3 2027

Phase 3Active, not recruiting

Study completion

NCT00572169

Q4 2027

Phase 2Active, not recruiting

Remission

NCT00869232

Q4 2029

Phase 3Active, not recruiting

Multiple Myeloma

NCT03710603

Clinical

Trials by Indication[1]

Multiple Myeloma28 trials

IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma

Completed·NNantes University Hospital·Phase 3·NCT00200681·493 enrolled

PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma

Unknown status·KKorean Multiple Myeloma Working Party·Phase 2·NCT00319865·47 enrolled

A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)

Terminated· Novartis logo

Novartis·Phase 2·NCT02720510·6 enrolled

Show 25 more trials

Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma

Unknown status·PProf Jamie Cavenagh·Phase 1/2·NCT02145715·54 enrolled

Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma

Terminated·NNYU Langone Health·Phase 2·NCT01438177·11 enrolled

Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma

Completed·UUniversity of Michigan Rogel Cancer Center·N/A·NCT00135187·30 enrolled

Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma

Completed·PPETHEMA Foundation·Phase 2·NCT01376401·60 enrolled

STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

Active, not recruiting·UUniversity of Turin, Italy·Phase 4·NCT03829371·450 enrolled

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT02195479·706 enrolled

Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00116961·40 enrolled

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT02136134·498 enrolled

A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT00911859·118 enrolled

Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients

Completed· Takeda logo

Takeda·Phase 1/2·NCT00507442·158 enrolled

Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma

Terminated·UUniversity of Arkansas·Phase 2·NCT00128921·18 enrolled

Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)

Completed·NNantes University Hospital·Phase 3·NCT01971658·358 enrolled

UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma

Completed·UUniversity of Arkansas·N/A·NCT00569868·11 enrolled

Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma

Active, not recruiting·SStichting European Myeloma Network·Phase 3·NCT03710603·709 enrolled

Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone

Completed·PPETHEMA Foundation·Phase 2·NCT01237249·250 enrolled

Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma

Completed· Sanofi logo

Sanofi·Phase 1·NCT01233895·26 enrolled

A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT03217812·220 enrolled

Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma

Terminated·—·Phase 2·NCT01729338·17 enrolled

A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT03234972·213 enrolled

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT01998971·240 enrolled

Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Terminated·NNantes University Hospital·Phase 2·NCT00337506·50 enrolled

VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)

Unknown status·MMichele Cavo·Phase 3·NCT01134484·480 enrolled

Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.

Completed·PPETHEMA Foundation·Phase 1/2·NCT00388635·60 enrolled

Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients

Terminated·UUniversity of Utah·Phase 2·NCT01720043·8 enrolled

Study of Induction Treatment With Velcade and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal Failure

Completed·PPETHEMA Foundation·Phase 2·NCT01084837·60 enrolled

Lymphoma7 trials

Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas

Completed·SSamsung Medical Center·Phase 1/2·NCT00374699·55 enrolled

A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01132911·5 enrolled

Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma

Completed·GGruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie·Phase 2·NCT00509379·48 enrolled

Show 4 more trials

Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma

Completed·OOhio State University Comprehensive Cancer Center·Phase 2·NCT00201877·25 enrolled

Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT01281917·40 enrolled

Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma

Terminated·HHoosier Cancer Research Network·Phase 2·NCT01186458·4 enrolled

Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma

Completed·LLymphoma Study Association·Phase 2·NCT00136565·60 enrolled

Follicular Lymphoma3 trials

A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma

Completed· Takeda logo

Takeda·Phase 2·NCT00636792·73 enrolled

Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab

Terminated· Takeda logo

Takeda·Phase 2·NCT00850499·12 enrolled

Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma

Completed· Takeda logo

Takeda·Phase 2·NCT00715208·55 enrolled

Treatment1 trial

VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates

Completed·KKorean Multiple Myeloma Working Party·Phase 2·NCT00320476·35 enrolled

Nasopharyngeal Carcinoma1 trial

Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma

Withdrawn·JJohns Hopkins University·Phase 2·NCT00367718

27 more indications

Minimal Residual Disease1 trial

First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade

Completed·VVanderbilt-Ingram Cancer Center·Phase 2·NCT01215344·36 enrolled

Kidney Transplant1 trial

Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients

Completed·UUniversity of Cincinnati·Phase 4·NCT00782821·40 enrolled

Relapsed AML1 trial

Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML

Completed·UUniversity of Kentucky·Phase 1·NCT00382954·55 enrolled

Remission1 trial

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Active, not recruiting·UUniversity of Arkansas·Phase 2·NCT00869232·90 enrolled

Relapsed/Refractory1 trial

Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM

Completed·SStanford University·Phase 1·NCT01114282·11 enrolled

AIN1 trial

Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM

Unknown status·KKorean Multiple Myeloma Working Party·Phase 2·NCT00378755·62 enrolled

Trial1 trial

Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

Active, not recruiting·UUniversity of Arkansas·Phase 2·NCT00871013·160 enrolled

Non-Small Cell Lung Cancer1 trial

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

Completed· Takeda logo

Takeda·Phase 2·NCT00343720

Relapsed or Refractory1 trial

Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults

Terminated·—·Phase 2·NCT02535806·2 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Completed· Takeda logo

Takeda·Phase 2·NCT01040871·164 enrolled

Vaginal Cancer1 trial

Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer

Terminated·WWomen and Infants Hospital of Rhode Island·Phase 2·NCT00106262·38 enrolled

Myeloma1 trial

Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00469209·60 enrolled

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1/2·NCT00237627·107 enrolled

Allogeneic Stem Cell Transplantation1 trial

Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation

Completed·MMassachusetts General Hospital·Phase 1·NCT02312102·22 enrolled

Adenocarcinoma1 trial

VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features

Terminated· Takeda logo

Takeda·Phase 2·NCT00117351

Amyloidosis1 trial

Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis

Completed· Takeda logo

Takeda·Phase 1/2·NCT00298766·70 enrolled

Myelodysplastic Syndromes1 trial

Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

Completed·OOhio State University Comprehensive Cancer Center·Phase 1·NCT00624936·23 enrolled

Lupus Nephritis1 trial

Velcade for Proliferative Lupus Nephritis

Withdrawn·TThe Rogosin Institute·Phase 4·NCT01169857

Myelodysplastic Syndrome1 trial

Velcade in Myelodysplastic Syndrome - Pilot Study

Terminated·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 2·NCT00440076·28 enrolled

Prostate Cancer1 trial

Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer

Terminated·MMedical University of South Carolina·Phase 2·NCT00103376·23 enrolled

T-Cell Prolymphocytic Leukemia1 trial

Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia

Withdrawn·SStanford University·Phase 2·NCT01162031

Leukemia1 trial

VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia

Completed·MMassachusetts General Hospital·Phase 1·NCT00505700·36 enrolled

Autologous Stem Cell Transplantation1 trial

Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients

Terminated·SShanghai Jiao Tong University School of Medicine·Phase 2/3·NCT00984828·23 enrolled

Advanced Cancer1 trial

Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00500422·134 enrolled

Unspecified4 trials

Study of Temsirolimus, Topotecan, and Bortezomib

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00770731·80 enrolled

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

Active, not recruiting·UUniversity of Arkansas·Phase 3·NCT00572169·177 enrolled

UARK 2003-33, Total Therapy III

Completed·UUniversity of Arkansas·Phase 2·NCT00081939·303 enrolled

Show 1 more trial

VELCADE,Rituximab,Cyclophosphamide and Decadron

Terminated·OOncology Specialists, S.C.·Phase 2·NCT00413959·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 70 trial records for Velcade. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Velcade compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Velcade. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Takeda

Velcade

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q4 2027

Q4 2029

Trials by Indication[1]

Multiple Myeloma28 trials

Lymphoma7 trials

Follicular Lymphoma3 trials

Treatment1 trial

Nasopharyngeal Carcinoma1 trial

Minimal Residual Disease1 trial

Kidney Transplant1 trial

Relapsed AML1 trial

Remission1 trial

Relapsed/Refractory1 trial

AIN1 trial

Trial1 trial

Non-Small Cell Lung Cancer1 trial

Relapsed or Refractory1 trial

Diffuse Large B-Cell Lymphoma1 trial

Vaginal Cancer1 trial

Myeloma1 trial

Transplantation1 trial

Cervical Cancer1 trial

Breast Cancer1 trial

Allogeneic Stem Cell Transplantation1 trial

Adenocarcinoma1 trial

Amyloidosis1 trial

Myelodysplastic Syndromes1 trial

Lupus Nephritis1 trial

Myelodysplastic Syndrome1 trial

Prostate Cancer1 trial

T-Cell Prolymphocytic Leukemia1 trial

Leukemia1 trial

Autologous Stem Cell Transplantation1 trial

Advanced Cancer1 trial

Unspecified4 trials

References

Drug Info

Quick Facts

Related News